Literature DB >> 3091257

Comparison of pharmacodynamic effects and plasma levels of oral and rectal ergotamine.

P M Bülow, J J Ibraheem, G Paalzow, P Tfelt-Hansen.   

Abstract

Plasma levels and the vasoconstrictive effect of 1 mg ergotamine tartrate given as tablets or suppositories were compared. In a crossover study, eight male volunteers received tablets or suppositories containing ergotamine in a drug combination (Anervan) and, as a control, suppositories without ergotamine. Blood sampling and measurement of toe-arm systolic gradients with a strain-gauge technique were done for up to 6 h and again after 24 h and 48 h. Only 29 of 160 blood samples contained detectable (greater than 0.1 ng/ml) amounts of ergotamine, and kinetic comparison could not be performed. Only ergotamine-containing suppositories caused a significant (p less than 0.008) decrease in toe-arm systolic gradient which was significantly different (p less than 0.003) from the effects of ergotamine tablets and control suppositories. Rectal ergotamine is thus more biologically active, for the factor used, than oral ergotamine. We suggest that a rectal dose of 1 mg ergotamine tartrate should be tried as the initial dose in the treatment of migraine attacks.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3091257     DOI: 10.1046/j.1468-2982.1986.0602107.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  2 in total

1.  The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double-blind, placebo-controlled, crossover study in normal subjects.

Authors:  Peer Tfelt-Hansen; Kaj Seidelin; Michael Stepanavage; Christopher Lines
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

Review 2.  Pharmacokinetics of rectal drug administration, Part II. Clinical applications of peripherally acting drugs, and conclusions.

Authors:  E J van Hoogdalem; A G de Boer; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.